Sanofi (NASDAQ:SNY) Receives $54.00 Average Price Target from Brokerages

Shares of Sanofi (NASDAQ:SNY) have earned an average rating of “Hold” from the fourteen analysts that are presently covering the stock, MarketBeat reports. Nine equities research analysts have rated the stock with a hold recommendation, four have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 12-month target price among brokers that have issued ratings on the stock in the last year is $54.00.

Several research firms have issued reports on SNY. Sanford C. Bernstein raised shares of Sanofi to a “strong-buy” rating in a research note on Thursday, March 19th. BNP Paribas Exane cut shares of Sanofi from an “outperform” rating to a “neutral” rating and set a $50.00 price target on the stock. in a research note on Monday, April 20th. Weiss Ratings raised shares of Sanofi from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Thursday, April 9th. Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating on shares of Sanofi in a research note on Friday, January 16th. Finally, UBS Group reissued a “neutral” rating on shares of Sanofi in a research report on Friday, January 16th.

Institutional Investors Weigh In On Sanofi

Hedge funds have recently modified their holdings of the stock. Flagship Harbor Advisors LLC acquired a new stake in shares of Sanofi in the fourth quarter worth approximately $25,000. Financial Consulate Inc. acquired a new stake in shares of Sanofi in the third quarter worth approximately $26,000. Physician Wealth Advisors Inc. boosted its position in shares of Sanofi by 180.5% in the first quarter. Physician Wealth Advisors Inc. now owns 589 shares of the company’s stock worth $28,000 after acquiring an additional 379 shares during the last quarter. Leonteq Securities AG boosted its position in shares of Sanofi by 95.8% in the first quarter. Leonteq Securities AG now owns 607 shares of the company’s stock worth $29,000 after acquiring an additional 297 shares during the last quarter. Finally, Measured Wealth Private Client Group LLC acquired a new stake in shares of Sanofi in the third quarter worth approximately $29,000. 14.03% of the stock is owned by institutional investors and hedge funds.

Sanofi Price Performance

Sanofi stock opened at $45.90 on Friday. Sanofi has a 12-month low of $43.32 and a 12-month high of $55.73. The stock has a market capitalization of $111.95 billion, a P/E ratio of 12.82, a P/E/G ratio of 1.16 and a beta of 0.42. The firm’s 50-day moving average is $46.41 and its two-hundred day moving average is $47.95. The company has a debt-to-equity ratio of 0.17, a current ratio of 1.01 and a quick ratio of 0.22.

Sanofi Increases Dividend

The business also recently announced an annual dividend, which will be paid on Wednesday, June 3rd. Investors of record on Monday, May 4th will be given a $2.4225 dividend. This is a boost from Sanofi’s previous annual dividend of $2.04. This represents a dividend yield of 502.0%. The ex-dividend date of this dividend is Monday, May 4th. Sanofi’s dividend payout ratio is 44.69%.

Sanofi Company Profile

Sanofi (NASDAQ:SNY) is a multinational pharmaceutical company headquartered in France that researches, develops, manufactures and markets prescription medicines, vaccines and consumer healthcare products. The company operates across multiple therapeutic areas, including immunology, rare diseases, oncology, cardiovascular and metabolic diseases, and vaccines through its Sanofi Pasteur division. Sanofi sells products to hospitals, clinics, governments and retail pharmacies, with a broad global footprint and significant presence in Europe, North America and emerging markets.

Key commercial offerings include specialty biologics and established small-molecule medicines.